MedPlus Health Services Limited has disclosed multiple regulatory actions affecting its subsidiary operations across different states, followed by a clarification regarding delayed disclosure compliance. The company informed stock exchanges about suspension orders received by Optival Health Solutions Private Limited, a wholly-owned subsidiary, from drug control authorities in Andhra Pradesh and Karnataka.

Latest Regulatory Development

The most recent action involves a suspension order from Karnataka authorities. The Assistant Director, Drugs Control Administration, Mandya Circle-Mandya Karnataka issued a three-day suspension for the store located at Guthal Road Mandya, Karnataka.

Previous Andhra Pradesh Action

Earlier, the subsidiary received another suspension order from Andhra Pradesh authorities targeting a different store location with more significant financial implications.

Disclosure Delay Clarification

On March 24, 2026, MedPlus Health Services issued a clarification to both BSE and NSE regarding the delay in disclosing these material events. The company acknowledged that the delay in meeting the prescribed 24-hour timeline was due to inadvertent oversight.

Legal Framework and Compliance

Both suspension orders were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. This regulatory framework governs the licensing and operation of pharmaceutical retail establishments across India. The company has assured that corrective measures have been implemented to ensure timely compliance with SEBI LODR Regulations going forward.

Combined Financial Impact

The regulatory actions across both states represent a cumulative potential revenue impact on the subsidiary's operations.

MedPlus Health Services Limited has informed stock exchanges about additional regulatory actions taken against its subsidiary company's retail pharmacy operations. The healthcare retailer disclosed that Optival Health Solutions Private Limited, a subsidiary, has now received multiple drug license suspension orders from state drug control authorities across different locations.

Regulatory Actions Across Multiple States

The subsidiary has faced enforcement actions from drug control administrations in Karnataka, Telangana, and Andhra Pradesh. All suspension orders were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

Updated Financial Impact Assessment

The company has quantified the potential financial impact of these regulatory actions. With the latest suspension order received on March 16, 2026, the combined potential revenue loss across all affected stores has increased to Rs 9.44 lacs. The newest Karnataka store suspension at Lingaraj Nagar carries a potential revenue loss of Rs 1.77 lacs for a five-day suspension period.

Latest Regulatory Compliance Disclosure

MedPlus Health Services made the latest disclosure under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company received the most recent suspension order on March 16, 2026, and reported the matter to stock exchanges on March 17, 2026. Company Secretary and Compliance Officer Manoj Kumar Srivastava signed the regulatory filing.

Documentation and Transparency

The company has committed to making complete details available on its official website at www.medplusindia.com . The information will also be accessible through BSE Limited and National Stock Exchange of India websites, ensuring transparency for all stakeholders and regulatory compliance. The latest filing follows SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, and SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024.